Navigation Links
MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease
Date:6/25/2009

NEW YORK, June 25 /PRNewswire-USNewswire/ -- As of mid-2009, The Michael J. Fox Foundation for Parkinson's Research has already funded over $1 million in high-risk, high-reward approaches to Parkinson's therapeutic development through its groundbreaking Rapid Response Innovation Awards. Projects include investigations of the safety and efficacy of an FDA-approved drug for kidney disease to treat Parkinson's; characterization of a tenuous link between PD and certain strains of influenza virus; and a proof-of-principle approach to refine deep brain stimulation (DBS) into a potentially more effective symptomatic therapy.

Rapid Response, one of the Foundation's Edmond J. Safra Core Programs for PD Research, earmarks up to $2 million annually to support research with little to no existing preliminary data, but potential to crack open entirely new ways of understanding or treating Parkinson's disease. The program has no deadline, instead accepting researchers' proposals on a rolling basis throughout the year in order to fund truly novel thinking whenever inspiration strikes.

"Rapid Response enables us to assess the best new ideas in real time, quickly vet their potential, and move the most promising ones to the next level fast," said Katie Hood, CEO of MJFF. "This reflects our commitment to keep fresh ideas flowing into the Parkinson's therapeutic pipeline, as well as our recognition that when great research ideas have to wait for a program deadline, so do PD patients -- a status quo we are determined to improve on."

Highlights of the 2009 program include:

  • Curt R. Freed, MD, of the University of Colorado has discovered that phenylbutyrate, a drug already approved by the U.S. FDA to treat kidney disease, prevents brain deterioration in pre-clinical models of Parkinson's. The drug may turn on a protective gene called DJ-1 in the brain. Dr. Freed is studying 12 people with recently diagnosed PD to determine if the drug can increase DJ-1 levels and set the stage for determining whether phenylbutyrate may slow disease progression.
  • Richard Smeyne, PhD, of Saint Jude Children's Research Hospital will test the hypothesis that the virulent H5N1 ("bird flu") strain of influenza virus can play a role in inducing parkinsonism. There is significant literature, mostly based on cases from the Spanish Influenza outbreak of 1918, documenting Parkinson's disease following exposure to flu virus. The researchers hypothesize that flu can induce aspects of PD including cell loss, as well as to show how viruses access the nervous system.
  • Wassilios Meissner, MD, PhD, of University Hospital Bordeaux (France) and Peter Tass, MD, PhD, of the University of Cologne (Germany) want to update deep brain stimulation surgery, taking advantage of new discoveries about the mechanisms of PD to expand DBS's benefit to a wider range of PD patients. With MJFF funding, they are working in a pre-clinical model of PD to assess the practical potential of modifying abnormal synchronization in the brain's basal ganglia region -- an approach that, according to preliminary theoretical studies, could result in functional improvements for PD patients.

The Foundation has funded 20 Rapid Response Innovation Awards in 2009, and a total of $6,081,627 in awards since the program was first launched. Some Rapid Response projects from prior years have gone on to garner major additional funding to support the next stage of research, including clinical trials. These include D. James Surmeier, PhD's 2007-2008 investigation of approved high-blood pressure drug isradipine as a neuroprotective approach to PD, which is currently being tested with MJFF support in a Phase 2 controlled clinical trial.

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $143 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
2. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
3. Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip
4. CyberKnife Radiosurgery for Lung Cancer Sees Increased Interest and Continued Rapid Growth
5. MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
6. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
7. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
8. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
9. Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology
10. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
11. Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 This report on the opioid induced ... of the global market. Large number of chronic pain ... constipation is a major side effect of consumption of ... targeted therapy has been prescribed to treat opioid induced ... medicines, and growing awareness about the therapy are the ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... ... Next week after January 20th, the fear for many is that the ... needs of over 30 million. Many interviews with Dr. Carol Francis at the Los ... were suppose to prioritize. Interviews provided below. , Among those present was ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... innovators, engineers, and scientists from around the world, announces the launch of its ... quick and easy portal to research breakthroughs and trending news, vital information on ...
(Date:1/19/2017)... Park City, Utah (PRWEB) , ... January 19, ... ... Sundance Film Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew ... Lounge to provide a condensed version of the clinic’s leading recovery program. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and ... has been condensed to a single page, maximizing usability and improving efficiency significantly ...
Breaking Medicine News(10 mins):